Developer docs
API playgroundTry for free, no card

Search company profiles

NOWDiagnostics

Full company profile

uuid0000zs5

Namestring
NOWDiagnostics
Legal namestring
NOWDiagnostics, Inc.
Websiteurl
nowdx.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

NOWDiagnostics, Inc. (NOWDx) is a Springdale, Arkansas-based developer and manufacturer of over-the-counter (OTC) and point-of-care (POC) rapid diagnostic tests, founded in 2013. The company's core offering is its proprietary "Touch to Test" platform — a patented buffer-less lateral flow architecture with sophisticated plasma separation microfluidics that enables virtually any immunological assay to be performed in a single step using a tiny amount of capillary blood or saliva, yielding results in minutes without buffers, reagents, or additional equipment. The platform is protected by 75+ issued and pending patents and supports a pipeline of 30+ tests. NOWDx markets two principal product lines: the First To Know consumer brand (anchored by the FDA De Novo authorized OTC syphilis test, the first and only rapid in-home syphilis test in the U.S., launched nationally in November 2024) and the ADEXUSDx professional brand (FDA-cleared hCG pregnancy test, COVID-19 antibody test under EUA, and CE-marked syphilis test), plus the Direct Collect sample collection device and acquired CELLMIC smartphone reader technology.

NOWDx monetizes primarily through one-time unit sales of diagnostic tests across three channels: (1) OTC consumer distribution via Amazon and 15,000+ retail pharmacy and drugstore locations nationwide, with First To Know Syphilis priced under $30; (2) professional and hospital distribution through an exclusive U.S. partnership with Labcorp (which is also a Series B co-investor), with ADEXUSDx hCG priced at $150 per unit and Labcorp OnDemand availability planned for 2025; and (3) public health distribution via the NASTAD/BHOC TakeMeHome initiative providing free tests to at-risk consumers. International distribution is handled through 14 distributors across 10 countries, leveraging CE Mark approvals. Manufacturing is conducted in a fully automated Springdale facility with 2 million tests per month capacity built in partnership with Kinematic. Ownership is held by venture investors including DigitalDx Ventures (Series B lead), Labcorp Venture Fund, Kompass Kapital Management, and BARDA (federal grant), with operating leadership recruited substantially from former OraSure Technologies executives, including CEO Lisa Nibauer (appointed May 2026), Board Chair Dr. Stephen Tang, CSO Dr. Jody Berry, and VP Sales Todd Grice.

Short descriptiontext

NOWDiagnostics develops and manufactures FDA-authorized over-the-counter and point-of-care rapid diagnostic tests using its proprietary Touch to Test platform, serving U.S. consumers, healthcare providers, and public health programs across retail, Labcorp professional, and TakeMeHome channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSpringdale, United States
HQ citystring
Springdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostic tests, point-of-care diagnostics, over-the-counter testing, lateral flow immunoassays, at-home health testing
Industry3 codes
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Rapid Diagnostic Tests
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Sales
TypeOne Time License
Description

One-time sale of rapid diagnostic tests including First To Know Syphilis Test and ADEXUSDx hCG Test through retail, pharmacy, online channels, and professional healthcare settings.

nowdx.com
2Professional Distribution Revenue
TypeOne Time License
Description

Revenue from Labcorp exclusive distribution partnership for First To Know Syphilis Test in professional and hospital settings.

nowdx.com
3OTC Consumer Sales
TypeOne Time License
Description

Direct-to-consumer sales of OTC tests through Amazon and retail pharmacy chains across 15,000+ locations nationwide.

nowdx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1First To Know Syphilis Test - OTC retail pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Under $30 per test, available at major retailers, pharmacies, drugstores nationwide and on Amazon

nowdx.com
2ADEXUSDx hCG Test - Professional use
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$150.00 per unit

nowdx.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1First To Know®
Description

Over-the-counter diagnostic test brand including the FDA-authorized First To Know Syphilis Test and First To Know Pregnancy Test (EU).

nowdx.com
+1 more record
Core offering1 text field

NOWDiagnostics develops and manufactures patented "Touch to Test" over-the-counter and point-of-care diagnostic tests that use a single drop of capillary blood or saliva and deliver results in minutes without buffers, reagents, or additional equipment. The company's commercial product lines include the First To Know OTC Syphilis Test (FDA De Novo authorized), the ADEXUSDx hCG professional pregnancy test (FDA 510(k) cleared), the ADEXUSDx COVID-19 Antibody Test (FDA EUA), and the CE Marked ADEXUSDx Syphilis rapid test, with 30+ additional tests in its development pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93.4% positive percent agreement (PPA) and 99.5% negative percent agreement (NPA) in clinical study of 1,270 people for First To Know Syphilis Test
+3 more records
Product overview1 text field

NOWDiagnostics (NOWDx) is a diagnostic test manufacturer offering two main product lines: First To Know (OTC consumer tests) and ADEXUSDx (professional/POC tests). The core offering is the proprietary Touch to Test technology platform, enabling one-step immunological assays using capillary blood or saliva with results in minutes. The flagship consumer product is the First To Know Syphilis Test (FDA-authorized OTC, August 2024), the only in-home syphilis test in the U.S. The ADEXUSDx line includes the FDA-cleared hCG pregnancy test, COVID-19 antibody test (EUA), and syphilis rapid test (CE Mark). Supporting products include Direct Collect sample collection device and CELLMIC smartphone readers (acquired technology). With 30+ tests in pipeline and 75+ patents, the company serves markets worldwide from its Springdale, Arkansas headquarters.

Product and service4 records
1First To Know Syphilis Test
CategoryConsumer OTC Diagnostic Test
Description

Over-the-counter rapid syphilis test delivering in-home results in 15 minutes from a single drop of capillary blood; detects Treponema pallidum antibodies using a patented buffer-less lateral flow device with 93.4% PPA and 99.5% NPA in a 1,270-person clinical study. Sold to consumers via Amazon, retail pharmacies, and the NASTAD/BHOC TakeMeHome initiative.

2ADEXUSDx hCG Test
CategoryProfessional Point-of-Care Diagnostic Test
Description

FDA 510(k)-cleared professional-use immunoassay for qualitative detection of human chorionic gonadotropin (hCG) in whole blood, plasma, or serum; delivers results in 10 minutes from a single fingerstick drop with 99% sensitivity and specificity, no reagents or equipment required. Used by clinicians for early pregnancy detection, including in hospital settings via the Labcorp distribution partnership.

3First To Know Pregnancy Test (EU)
CategoryConsumer OTC Diagnostic Test (EU)
Description

Blood-based pregnancy test for the European market that detects pregnancy earlier than urine-based tests; sold OTC in Europe following EC approval.

4ADEXUSDx COVID-19 Antibody Test
CategoryProfessional Point-of-Care Diagnostic Test
Description

Self-contained rapid serology assay measuring SARS-CoV-2 antibodies (IgA, IgG, IgM); delivers results in 15 minutes from a single drop of fingerstick blood with no buffers, reagents, or additional equipment required; FDA EUA authorized for point-of-care use and CE Marked.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-01-22
Description

Collaboration through TakeMeHome initiative to address growing syphilis epidemic by expanding access to in-home testing. NASTAD provides public health expertise and program infrastructure for free test distribution.

2BHOC (Building Healthy Online Communities)
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-01-22
Description

TakeMeHome initiative partner with ability to engage communities through digital platforms. Provides discreet and easy-to-use testing kits with educational resources.

nowdx.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-16
Description

Exclusive U.S. distributor of First To Know Syphilis Test in professional and hospital settings. Labcorp to offer test through extensive distribution network and Labcorp OnDemand in 2025. Also U.S. distribution partner for ADEXUSDx hCG test in hospital settings.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of rapid diagnostic tests including the OraQuick HIV, HCV and Ebola tests. Most direct comparable in rapid immunoassay/OTC diagnostics, and currently litigation counterpart of NOWDx. Both companies target decentralized testing for infectious disease with similar lateral-flow technology.

TypeBroad incumbent
Description

Manufacturer of clinical diagnostics including rapid test platforms and quality controls for clinical labs. Overlaps with NOWDx in IVD test manufacturing and clinical diagnostic workflows.

TypeBroad incumbent
Description

Women's health and diagnostics leader (Aptima, Panther) with growing rapid-test footprint. Adjacent in women's health and STI testing categories where NOWDx's hCG and syphilis tests compete.

TypeBroad incumbent
Description

Major medical technology company with a large diagnostics segment including rapid molecular and immunoassay tests (e.g., BD Veritor). Provides both competition and potential partnership context for NOWDx's POC ambitions.

TypeDirect peer
Description

Specialty rapid point-of-care diagnostics company focused on infectious disease detection (HIV, syphilis, COVID-19, Zika). Highly comparable in product mix (rapid immunodiagnostics for STI and infectious disease), regulatory pathway, and target customers (clinics, public health, OTC).

TypeBroad incumbent
Description

Global diagnostics company offering rapid test systems (e.g., OSOM) for infectious disease and women's health including hCG. Comparable product mix and channels (OTC, professional) to NOWDx's ADEXUSDx and First To Know lines.

TypeDirect peer
Description

Developer and manufacturer of diagnostic tests for infectious disease, HbA1c, and other analytes using both lab-based and rapid/point-of-care formats. Comparable in target customers (clinical labs, public health) and syphilis/HIV test focus.

8Lucira Health (Pfizer)
TypeEmerging player
Description

At-home molecular diagnostic test platform (COVID-19, Flu) positioned at the OTC/at-home intersection. Represents the emerging class of OTC molecular diagnostics that NOWDx aims to enter with its planned Strep Throat test.

TypeBroad incumbent
Description

Large diagnostics manufacturer offering rapid immunoassays (QuickVue), Sofia platform, and a broad portfolio of clinical diagnostics and OTC tests. Overlap with NOWDx in point-of-care and OTC infectious-disease testing at much larger scale.

10Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics giant producing rapid tests such as Binax and the Panbio COVID-19 test, plus extensive POC and OTC offerings. Comparable technology architecture and end markets; far larger scale and distribution.

Market position
Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NOWDiagnostics

Rapid Diagnostic Testsnowdx.com

NOWDiagnostics develops and manufactures FDA-authorized over-the-counter and point-of-care rapid diagnostic tests using its proprietary Touch to Test platform, serving U.S. consumers, healthcare providers, and public health programs across retail, Labcorp professional, and TakeMeHome channels.

What NOWDiagnostics does

NOWDiagnostics, Inc. (NOWDx) is a Springdale, Arkansas-based developer and manufacturer of over-the-counter (OTC) and point-of-care (POC) rapid diagnostic tests, founded in 2013. The company's core offering is its proprietary "Touch to Test" platform — a patented buffer-less lateral flow architecture with sophisticated plasma separation microfluidics that enables virtually any immunological assay to be performed in a single step using a tiny amount of capillary blood or saliva, yielding results in minutes without buffers, reagents, or additional equipment. The platform is protected by 75+ issued and pending patents and supports a pipeline of 30+ tests. NOWDx markets two principal product lines: the First To Know consumer brand (anchored by the FDA De Novo authorized OTC syphilis test, the first and only rapid in-home syphilis test in the U.S., launched nationally in November 2024) and the ADEXUSDx professional brand (FDA-cleared hCG pregnancy test, COVID-19 antibody test under EUA, and CE-marked syphilis test), plus the Direct Collect sample collection device and acquired CELLMIC smartphone reader technology.

NOWDx monetizes primarily through one-time unit sales of diagnostic tests across three channels: (1) OTC consumer distribution via Amazon and 15,000+ retail pharmacy and drugstore locations nationwide, with First To Know Syphilis priced under $30; (2) professional and hospital distribution through an exclusive U.S. partnership with Labcorp (which is also a Series B co-investor), with ADEXUSDx hCG priced at $150 per unit and Labcorp OnDemand availability planned for 2025; and (3) public health distribution via the NASTAD/BHOC TakeMeHome initiative providing free tests to at-risk consumers. International distribution is handled through 14 distributors across 10 countries, leveraging CE Mark approvals. Manufacturing is conducted in a fully automated Springdale facility with 2 million tests per month capacity built in partnership with Kinematic. Ownership is held by venture investors including DigitalDx Ventures (Series B lead), Labcorp Venture Fund, Kompass Kapital Management, and BARDA (federal grant), with operating leadership recruited substantially from former OraSure Technologies executives, including CEO Lisa Nibauer (appointed May 2026), Board Chair Dr. Stephen Tang, CSO Dr. Jody Berry, and VP Sales Todd Grice.

NOWDiagnostics firmographics

Firmographics
Name
NOWDiagnostics
Legal name
NOWDiagnostics, Inc.
Website
https://nowdx.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
NOWDiagnostics develops and manufactures FDA-authorized over-the-counter and point-of-care rapid diagnostic tests using its proprietary Touch to Test platform, serving U.S. consumers, healthcare providers, and public health programs across retail, Labcorp professional, and TakeMeHome channels.
Ownership category
akta.pro rank

NOWDiagnostics industry classification

Industry
Product category
Rapid Diagnostic Tests
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Rapid diagnostic tests
  • Point-of-care diagnostics
  • Over-the-counter testing
  • Lateral flow immunoassays
  • At-home health testing

Where NOWDiagnostics is headquartered

Location

Headquarters

HQ city
Springdale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NOWDiagnostics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Test Sales: One-time sale of rapid diagnostic tests including First To Know Syphilis Test and ADEXUSDx hCG Test through retail, pharmacy, online channels, and professional healthcare settings.
  2. Professional Distribution Revenue: Revenue from Labcorp exclusive distribution partnership for First To Know Syphilis Test in professional and hospital settings.
  3. OTC Consumer Sales: Direct-to-consumer sales of OTC tests through Amazon and retail pharmacy chains across 15,000+ locations nationwide.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goFirst To Know Syphilis Test - OTC retail pricing
Unit PricingPay-as-you-goADEXUSDx hCG Test - Professional use

Go-to-market motion5 records

Distribution channels5 records

Marketing channels5 records

NOWDiagnostics product offering

Product offering

Core offering

NOWDiagnostics develops and manufactures patented "Touch to Test" over-the-counter and point-of-care diagnostic tests that use a single drop of capillary blood or saliva and deliver results in minutes without buffers, reagents, or additional equipment. The company's commercial product lines include the First To Know OTC Syphilis Test (FDA De Novo authorized), the ADEXUSDx hCG professional pregnancy test (FDA 510(k) cleared), the ADEXUSDx COVID-19 Antibody Test (FDA EUA), and the CE Marked ADEXUSDx Syphilis rapid test, with 30+ additional tests in its development pipeline.

Product overview

NOWDiagnostics (NOWDx) is a diagnostic test manufacturer offering two main product lines: First To Know (OTC consumer tests) and ADEXUSDx (professional/POC tests). The core offering is the proprietary Touch to Test technology platform, enabling one-step immunological assays using capillary blood or saliva with results in minutes. The flagship consumer product is the First To Know Syphilis Test (FDA-authorized OTC, August 2024), the only in-home syphilis test in the U.S. The ADEXUSDx line includes the FDA-cleared hCG pregnancy test, COVID-19 antibody test (EUA), and syphilis rapid test (CE Mark). Supporting products include Direct Collect sample collection device and CELLMIC smartphone readers (acquired technology). With 30+ tests in pipeline and 75+ patents, the company serves markets worldwide from its Springdale, Arkansas headquarters.

Differentiator

Problem solved

Functional benefit

Brands

  • First To Know®: Over-the-counter diagnostic test brand including the FDA-authorized First To Know Syphilis Test and First To Know Pregnancy Test (EU).
  • ADEXUSDx®

Products and services

  • First To Know Syphilis Test Over-the-counter rapid syphilis test delivering in-home results in 15 minutes from a single drop of capillary blood; detects Treponema pallidum antibodies using a patented buffer-less lateral flow device with 93.4% PPA and 99.5% NPA in a 1,270-person clinical study. Sold to consumers via Amazon, retail pharmacies, and the NASTAD/BHOC TakeMeHome initiative.
  • ADEXUSDx hCG Test FDA 510(k)-cleared professional-use immunoassay for qualitative detection of human chorionic gonadotropin (hCG) in whole blood, plasma, or serum; delivers results in 10 minutes from a single fingerstick drop with 99% sensitivity and specificity, no reagents or equipment required. Used by clinicians for early pregnancy detection, including in hospital settings via the Labcorp distribution partnership.
  • First To Know Pregnancy Test (EU) Blood-based pregnancy test for the European market that detects pregnancy earlier than urine-based tests; sold OTC in Europe following EC approval.
  • ADEXUSDx COVID-19 Antibody Test Self-contained rapid serology assay measuring SARS-CoV-2 antibodies (IgA, IgG, IgM); delivers results in 15 minutes from a single drop of fingerstick blood with no buffers, reagents, or additional equipment required; FDA EUA authorized for point-of-care use and CE Marked.

Quantifiable outcome

  • 93.4% positive percent agreement (PPA) and 99.5% negative percent agreement (NPA) in clinical study of 1,270 people for First To Know Syphilis Test
  • +3 more outcomes

Companies that use NOWDiagnostics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

NOWDiagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

NOWDiagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • NASTAD (National Alliance of State and Territorial AIDS Directors)majorGTM or Marketing Partner · 22 January 2025Collaboration through TakeMeHome initiative to address growing syphilis epidemic by expanding access to in-home testing. NASTAD provides public health expertise and program infrastructure for free test distribution.
  • BHOC (Building Healthy Online Communities)majorGTM or Marketing Partner · 22 January 2025TakeMeHome initiative partner with ability to engage communities through digital platforms. Provides discreet and easy-to-use testing kits with educational resources.
  • LabcorpcoreChannel Partner/ Reseller/ Distributor · 16 October 2024Exclusive U.S. distributor of First To Know Syphilis Test in professional and hospital settings. Labcorp to offer test through extensive distribution network and Labcorp OnDemand in 2025. Also U.S. distribution partner for ADEXUSDx hCG test in hospital settings.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

NOWDiagnostics competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: Developer of rapid diagnostic tests including the OraQuick HIV, HCV and Ebola tests. Most direct comparable in rapid immunoassay/OTC diagnostics, and currently litigation counterpart of NOWDx. Both companies target decentralized testing for infectious disease with similar lateral-flow technology.
  • Chembio Diagnostics: Specialty rapid point-of-care diagnostics company focused on infectious disease detection (HIV, syphilis, COVID-19, Zika). Highly comparable in product mix (rapid immunodiagnostics for STI and infectious disease), regulatory pathway, and target customers (clinics, public health, OTC).
  • Trinity Biotech: Developer and manufacturer of diagnostic tests for infectious disease, HbA1c, and other analytes using both lab-based and rapid/point-of-care formats. Comparable in target customers (clinical labs, public health) and syphilis/HIV test focus.

Broad incumbents

  • Bio-Rad Laboratories: Manufacturer of clinical diagnostics including rapid test platforms and quality controls for clinical labs. Overlaps with NOWDx in IVD test manufacturing and clinical diagnostic workflows.
  • Hologic: Women's health and diagnostics leader (Aptima, Panther) with growing rapid-test footprint. Adjacent in women's health and STI testing categories where NOWDx's hCG and syphilis tests compete.
  • Becton Dickinson (BD): Major medical technology company with a large diagnostics segment including rapid molecular and immunoassay tests (e.g., BD Veritor). Provides both competition and potential partnership context for NOWDx's POC ambitions.
  • Sekisui Diagnostics: Global diagnostics company offering rapid test systems (e.g., OSOM) for infectious disease and women's health including hCG. Comparable product mix and channels (OTC, professional) to NOWDx's ADEXUSDx and First To Know lines.
  • QuidelOrtho: Large diagnostics manufacturer offering rapid immunoassays (QuickVue), Sofia platform, and a broad portfolio of clinical diagnostics and OTC tests. Overlap with NOWDx in point-of-care and OTC infectious-disease testing at much larger scale.
  • Abbott Diagnostics: Global diagnostics giant producing rapid tests such as Binax and the Panbio COVID-19 test, plus extensive POC and OTC offerings. Comparable technology architecture and end markets; far larger scale and distribution.

Emerging players

  • Lucira Health (Pfizer): At-home molecular diagnostic test platform (COVID-19, Flu) positioned at the OTC/at-home intersection. Represents the emerging class of OTC molecular diagnostics that NOWDx aims to enter with its planned Strep Throat test.

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

NOWDiagnostics social profiles

Digital presence

NOWDiagnostics compliance and trust

Trust signal

Compliance7 records

NOWDiagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NOWDiagnostics leadership team

Management profile

Number of profiles

Profiles6 records

NOWDiagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

NOWDiagnostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NOWDiagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOWDiagnostics

What does NOWDiagnostics do?

NOWDiagnostics develops and manufactures patented "Touch to Test" over-the-counter and point-of-care diagnostic tests that use a single drop of capillary blood or saliva and deliver results in minutes without buffers, reagents, or additional equipment. The company's commercial product lines include the First To Know OTC Syphilis Test (FDA De Novo authorized), the ADEXUSDx hCG professional pregnancy test (FDA 510(k) cleared), the ADEXUSDx COVID-19 Antibody Test (FDA EUA), and the CE Marked ADEXUSDx Syphilis rapid test, with 30+ additional tests in its development pipeline.

Is NOWDiagnostics a public or private company?

NOWDiagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was NOWDiagnostics founded?

NOWDiagnostics was founded in 2013. It employs 11 to 50 people.

Where is NOWDiagnostics based?

NOWDiagnostics is headquartered in Springdale, United States, in the North America region.

How does NOWDiagnostics make money?

Three revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are professional Distribution Revenue and OTC Consumer Sales.

Who are NOWDiagnostics's main competitors?

Direct peers on record are OraSure Technologies, Chembio Diagnostics and Trinity Biotech. Broad incumbents are Bio-Rad Laboratories, Hologic, Becton Dickinson (BD), Sekisui Diagnostics, QuidelOrtho and Abbott Diagnostics. Lucira Health (Pfizer) is listed as an emerging player.

Does NOWDiagnostics have an API?

No public API is recorded for NOWDiagnostics.

What industry is NOWDiagnostics in?

NOWDiagnostics's product category is Rapid Diagnostic Tests. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 325413 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNOWDiagnostics Appoints Lisa Nibauer as Chief Executive Officer to Lead Next Phase of Innovation and TransformationNOWDiagnostics appointed Lisa Nibauer as CEO, replacing Rob Weigle, who will become an advisor. Nibauer brings over 25 years of healthcare leadership, including roles at OraSure and BD. She will lead the company's next phase of innovation and transformation.SliceofhealthcareNOWDiagnostics Raises $22.5 Million in Series B Financing to Advance At-Home Diagnostic TestsNOWDiagnostics secured $22.5 million in Series B financing led by DigitalDx Ventures to commercialize its at-home diagnostic tests and expand its product pipeline. The funding round included participation from notable investors such as Labcorp Venture Fund and Kompass Kapital Management, validating the company's platform which holds over 75 patents.Clinical Lab ProductsRapid Syphilis Testing Access ExpandedLabcorp and NOWDiagnostics have partnered to distribute free rapid syphilis test kits to over 15 public health organizations across the United States to address a surge in infections. The initiative utilizes the First to Know Syphilis Test, which provides results in 15 minutes, aiming to improve early detection among high-risk populations such as LGBTQ+ communities and safety-net clinic patients. This distribution aligns with Labcorp’s broader strategy to expand access to self-collection STI testing solutions.LinkedInCracking the Diligence Code for At-Home Testing Businesses: Operational Considerations for Financial BuyersDeloitte experts outline operational diligence frameworks for private equity firms evaluating at-home testing businesses, highlighting key areas such as laboratory capacity, manufacturing, and logistics. The report identifies Binx Health, NOWDiagnostics, SiPhoX Health, Lifetime Health, LetsGetChecked, and Truepill as recent examples of companies securing funding or acquisitions in the sector.ArkansasbusinessNOWDiagnostics Faces Off With Biotech Rival In Trade Secrets LawsuitOraSure Technologies filed a lawsuit in U.S. District Court against rival NOWDiagnostics, alleging that a former employee stole confidential research and trade secrets when she joined the competitor in August. OraSure claims the employee concealed her departure for three weeks while misappropriating protected information from its R&D department, which represents years of work and significant investment.Clinical Lab ProductsFDA-Authorized At-Home Syphilis Test Available NationwideNOWDiagnostics has launched the First To Know Syphilis Test, becoming the first FDA-authorized over-the-counter syphilis test available for purchase nationwide in the U.S. The self-directed rapid test provides results in 15 minutes from a drop of blood and is priced under $30 to address rising syphilis cases and improve accessibility. This release aims to reduce stigma and support public health initiatives by allowing private, convenient testing across all 50 states.QuartzThe FDA just approved the first at-home test for syphilisThe U.S. Food and Drug Administration approved the first over-the-counter at-home test for syphilis, developed by NOWDiagnostics, which provides results in 15 minutes from a blood sample. This approval aims to increase screening rates and reduce infection spread amid an 80% rise in U.S. cases between 2018 and 2022.MedTech DiveFDA OKs first at-home syphilis testThe U.S. Food and Drug Administration granted market authorization to NowDiagnostics for its First To Know Syphilis Test, marking the first FDA-approved at-home syphilis diagnostic. The rapid test delivers results in 15 minutes using a single drop of blood, aiming to increase screening rates amid an 80% rise in U.S. syphilis cases between 2018 and 2022.AJMCNew At-Home Syphilis Test Has Potential to Save Lives and MoneyThe FDA authorized the First To Know Syphilis Test from NOWDiagnostics on August 16, 2024, an over-the-counter at-home test that detects syphilis within 15 minutes. The test costs $29.98 and has a 99.5% accuracy rate for negative specimens and 93.4% for positive ones. The company plans to make the test free through federal and state agencies.EatgFDA approves first at-home syphilis testThe FDA has granted marketing authorization for NOWDiagnostics’ First To Know Syphilis Test, becoming the first at-home, over-the-counter test for detecting syphilis antibodies. The device provides results in 15 minutes and demonstrated high accuracy rates in clinical studies involving 1,270 participants. This approval aims to improve public health access by allowing consumers to screen for syphilis privately, addressing rising infection rates in the United States.